Neuland Laboratories Ltd. · NSE:NEULANDLAB

Neuland Laboratories — Merger or Acquisition (2016)

12 slides from Neuland Laboratories's merger presentation, 2016

  1. Slide 1: Scheme of Arrangement and Rationale

    Scheme of Arrangement and Rationale Neuland Laboratories BSE CODE : 524558 | NSE SYMBOL : NEULANDLAB | BLOOMBERG: NLL:IN | REUTERS: NEUL.NS © 2016, Neuland Laboratories Limited. All Rights Reserved

  2. Slide 2: Safe Harbour

    Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "

  3. Slide 3: Current Group Structure

    Current Group Structure Neuland Health Sciences Pvt. Ltd.(NHSPL) (Peptides Research and Marketing) Promoter Group holding: 67.11% Others holding: 32.89% Neuland Laboratories Ltd.(NLL) Neuland Pharma Research Pvt. Ltd.(NPRPL) NHSPL: 51.67% (Research and Contract Manufacturing Services) Promoters/Prom

  4. Slide 4: Transaction Structure

    Transaction Structure © 2016, Neuland Laboratories Limited. All Rights Reserved

  5. Slide 5: Transaction Structure

    Transaction Structure Appointed Date April 1st, 2016 Scheme to involve share exchange 552 equity shares of NLL for every 1000 equity shares of NHSPL* Terms 410 equity shares of NLL for every 100 equity shares of NPRPL^ Intercompany shareholding will be cancelled# Pre Merger Post Merger Shareholding

  6. Slide 6: Rationale of Scheme

    Rationale of Scheme The amalgamation will build more stronger and sustainable business and enhance the potential for future growth. Combined entity with strong financials will have greater access to sources of funds, improved cash flows and increased net worth. Consolidation of intellectual property

  7. Slide 7: Valuation Overview

    Valuation Overview Valuation analysis has been undertaken by independent Valuation firm, Deloitte Haskins & Sells Valuation methodology based on commonly used and accepted methods to the extent relevant and applicable including Comparable Companies Multiples method / Earnings Capitalisation Value me

  8. Slide 8: Expected Timelines

    Expected Timelines Q3 FY17 Approval by Boards Application to BSE and NSE of all companies Jurisdictional High approval and announcement Court/NCLT Court Convened Transaction Shareholders and High Court approval completion Creditors approval Expected by Q2 FY18 8

  9. Slide 9: Post Merger Structure

    Post Merger Structure Promoters/Promoter Group: 41.29% Public: 58.71% Neuland Laboratories Inc Neuland Laboratories, K.K. NLL holding : 100% NLL holding : 100% More stronger and sustainable organization with enhanced potential for future growth 9

  10. Slide 10: Annexure

    Annexure © 2016, Neuland Laboratories Limited. All Rights Reserved

  11. Slide 11: Pre and post merger shareholding

    Pre and post merger shareholding Sl. Category of Shareholder Pre-merger % Post merger % No 1 Promoter & Promoter Group (a+b) 51.68 41.29 a. Neuland Health Sciences Private limited 51.67 - - Promoters & Promoter Group individuals 34.68 - - Non-Promoters 17.00 - b. Promoters & Promoter Group individua

  12. Slide 12: For further information contact: IR Desk

    For further information contact: IR Desk Ankit Gupta Neuland Labs Christensen IR +91 40 3021 1600 +91 22 4215 0210 ir@Neulandlabs.com ankitgupta@christensenir.com

Neuland Laboratories — Merger or Acquisition (2016) on 6ix